Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Postmenopausal: early-phase trial registry

2 of 10 indexed Postmenopausal trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Postmenopausal: 10 US clinical trials tracked, 2 recruiting.

Postmenopausal is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Warner Chilcott, running 1 of these trials.

Enrollment posture brief

Registry condition postmenopausal

OPEN 2 | RECR 20% | LATE 0 | EARLY 4 | RANK #1724 | SPON 1

Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Postmenopausal (this)20%
Open-enrollment share among volume-matched conditions near Postmenopausal

Postmenopausal lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Postmenopausal on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Postmenopausal is recruiting below its size-band peers.

    2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Postmenopausal trials is spread across many organizations.

    Warner Chilcott accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Postmenopausal trials plan to enrol fewer than 100 people.

    Median target enrolment is 72 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Postmenopausal research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Open and recent trials

10 total, page 1 of 1

RECRUITING NA 90 participants

Protein and Exercise for Postmenopausal Women's Wellbeing

University of Arkansas, Fayetteville

NCT06849817

RECRUITING NA 46 participants

Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women

Loma Linda University

NCT06445842

COMPLETED Phase 2 370 participants

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

Warner Chilcott

NCT00577837

COMPLETED Phase 2 297 participants

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Janssen Research & Development

NCT01381874

COMPLETED Phase 2 230 participants

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

NCT03180294

COMPLETED NA 72 participants

Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors

University of Vermont

NCT01482702

COMPLETED NA 50 participants

Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors

City of Hope Medical Center

NCT02235051

COMPLETED NA 50 participants

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer

University of Michigan Rogel Cancer Center

NCT06228768

COMPLETED Phase 1 37 participants

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

M.D. Anderson Cancer Center

NCT02152943

COMPLETED NA 27 participants

Weight Bearing Exercise in Preventing Frailty in Stage I-IIIA Breast Cancer Survivors

University of Arizona

NCT03708055

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Named interventions

Most-linked intervention names on Postmenopausal records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

experimental Drug
1 trials
Bupropion 150 mg XL Drug
1 trials
weight loss intervention Behavioral
1 trials
Abiraterone acetate + Prednisone or Prednisolone Drug
1 trials
Abiraterone acetate + Prednisone/ Prednisolone + Exemestane Drug
1 trials
risedronate Drug
1 trials
Acupressure Other
1 trials
Weight Loss Behavioral
1 trials

US sites by state

Facility locations filed on Postmenopausal trials. A trial with sites in several states counts in each.

California 4 trials
Texas 3 trials
Michigan 2 trials
Vermont 1 trials
South Dakota 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Postmenopausal page

10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Postmenopausal trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Warner Chilcott sponsors the most Postmenopausal trials on record, review their full trial history before evaluating a specific study. See Warner Chilcott's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Postmenopausal condition card totals 10 registered trials; most-linked intervention experimental; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.